Analysts’ Recent Ratings Updates for Amgen (AMGN)

Several brokerages have updated their recommendations and price targets on shares of Amgen (NASDAQ: AMGN) in the last few weeks:

• 1/8/2026 – Amgen had its price target raised by analysts at Truist Financial Corporation from $318.00 to $319.00. They now have a “hold” rating on the stock.
• 1/7/2026 – Amgen was upgraded by analysts at UBS Group AG to a “strong-buy” rating.
• 1/6/2026 – Amgen is now covered by analysts at UBS Group AG. They set a “buy” rating and a $380.00 price target on the stock.
• 12/30/2025 – Amgen had its price target raised by analysts at Argus from $310.00 to $360.00. They now have a “buy” rating on the stock.
• 12/29/2025 – Amgen had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Amgen had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Amgen had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Amgen was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/12/2025 – Amgen had its price target lowered by analysts at Morgan Stanley from $329.00 to $304.00. They now have an “equal weight” rating on the stock.
• 12/10/2025 – Amgen had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $425.00 price target on the stock.
• 12/10/2025 – Amgen had its price target raised by analysts at Wells Fargo & Company from $300.00 to $325.00. They now have an “equal weight” rating on the stock.
• 12/7/2025 – Amgen was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/5/2025 – Amgen was upgraded by analysts at Erste Group Bank AG from a “hold” rating to a “buy” rating.
• 12/3/2025 – Amgen had its price target raised by analysts at BMO Capital Markets from $335.00 to $372.00. They now have an “outperform” rating on the stock.
• 11/29/2025 – Amgen was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/25/2025 – Amgen was given a new $400.00 price target on by analysts at Wells Fargo & Company.
• 11/25/2025 – Amgen had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
• 11/24/2025 – Amgen is now covered by analysts at Truist Financial Corporation. They set a “hold” rating and a $318.00 price target on the stock.
• 11/19/2025 – Amgen had its price target raised by analysts at HSBC Holdings plc from $343.00 to $381.00. They now have a “buy” rating on the stock.
• 11/18/2025 – Amgen had its price target raised by analysts at Daiwa Capital Markets from $310.00 to $370.00. They now have an “outperform” rating on the stock.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is currently 73.57%.

Insider Transactions at Amgen

In related news, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 10,908 shares of company stock worth $3,674,966. 0.69% of the stock is currently owned by insiders.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.